Conference Coverage
In MS, the challenges for women are unique
SEATTLE – In treating women with MS, sexuality, pregnancy, and menopause all require specific attention.
Conference Coverage
Pediatric MS often goes untreated in the year after diagnosis
SEATTLE – About 65% of patients with pediatric multiple sclerosis do not receive disease-modifying therapy (DMT) within 1 year of diagnosis....
Video
Steady advances made since recognition of neuromyelitis optica 20 years ago
SEATTLE – Dr. Brian Weinshenker discusses the progress made in understanding and managing neuromyelitis optica.
Conference Coverage
Restless legs syndrome in MS linked to cognitive impairment
SEATTLE – Sleep dysfunction could be the key link, study suggests.
Video
Developing new measurements for better MS outcomes
SEATTLE – Researchers are working on developing more sensitive ways of measuring MS disease status.
Conference Coverage
Mindfulness meditation may boost cognition in MS
SEATTLE – Brief mindfulness meditation may improve cognitive processing speed in patients with MS more than adaptive computerized cognitive...
Conference Coverage
Switching from interferon beta-1a to alemtuzumab improves MS outcomes
SEATTLE – The switch is associated with a high rate of freedom from relapse and a reduced rate of brain volume loss...
Conference Coverage
MS patients pay big price for breaks from DMT
SEATTLE – They suffer more relapses, hospitalizations, and ER visits, a study finds, and nondrug costs are higher.
Conference Coverage
Low baseline heart rate may not increase cardiac risk when starting fingolimod
SEATTLE – First-dose cardiac events with fingolimod are rare, regardless of whether first-dose observations occur in clinic or at home.
Conference Coverage
Group creates three-step algorithm for the management of MS relapse
SEATTLE – Distinguishing a multiple sclerosis relapse from a pseudorelapse is essential, according to a consensus statement.
Conference Coverage
Fingolimod reduces MS disease activity, compared with glatiramer acetate
SEATTLE – In patients with relapsing multiple sclerosis, 0.5 mg/day fingolimod reduces the annualized relapse rate...
Conference Coverage
Hazardous cannabis use in MS linked to anxiety, depression
SEATTLE – But it is not clear if there is a cause-and-effect relationship.
Conference Coverage
Adherence to oral treatments for MS is poor
SEATTLE – One in three patients with MS has a lapse in oral therapy that lasts for at least 30 days, and...
Conference Coverage
Extended-release arbaclofen reduces MS-related spasticity
SEATTLE – A regimen of twice-daily, extended-release arbaclofen could reduce the adverse events associated with...
Conference Coverage
Why aren’t preferred DMTs prescribed for MS? Neurologists point to insurers, patients
SEATTLE – Survey pinpoints reasons why various types of MS therapies aren’t initiated.
Conference Coverage
Modest evidence for benefit in studies of cannabis in MS
SEATTLE – Trials vary widely in quality, review finds, and most focused on Sativex.
Conference Coverage
Alemtuzumab provides greater reductions in serum NfL than interferon beta-1a
Seattle – The results are consistent with alemtuzumab’s superior efficacy, compared with interferon beta-1a, but the...
Conference Coverage
Multimedia
Question 1 of 5